What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

The market expects Moderna (MRNA) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about "a ...

Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from ...

Moderna Inc (NASDAQ:MRNA) shares are flat Wednesday morning after a nearly 5% surge on Tuesday. Here’s what investors need to know. What To Know: Tuesday’s rally was driven by the release of positive ...

In the latest trading session, Moderna (MRNA) closed at $25.51, marking a +2.03% move from the previous day. This change outpaced the S&P 500's 0.48% gain on the day. On the other hand, the Dow ...

Shares of Moderna MRNA were up 4% yesterday after the company announced positive preliminary immunogenicity data from an ongoing phase IV study, which evaluated the updated version of its COVID-19 ...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA ...